The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 25, 2026
Filed:
Feb. 10, 2023
Applicant:
Kite Pharma, Inc., Santa Monica, CA (US);
Inventors:
Rajul Jain, Santa Monica, CA (US);
Remus Vezan, Los Angeles, CA (US);
Assignee:
Kite Pharma, Inc., Santa Monica, CA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 31/573 (2006.01); A61K 39/395 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61P 35/02 (2006.01); A61P 37/06 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2866 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61P 35/02 (2018.01); C07K 14/70503 (2013.01); A61K 2239/38 (2023.05); A61K 2239/48 (2023.05);
Abstract
The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.